Cheyenne Valley CBD Oil Stock

With global CBD sales potentially hitting $22 billion by 2022, here are four CBD stocks you'll want to know about. The FDA’s approval of CBD can change the trajectory of these stocks quickly. If regulators get out of the way, these companies could soar. The rampant growth of the cannabis industry has sparked investor interest in CBD oil stocks. Consider investing in these stocks to grow your portfolio organically.

4 Stocks Giving Investors Direct Exposure to CBD

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

OTC: MJNA

Medical Marijuana, Inc.

With global CBD sales potentially hitting $22 billion by 2022, here are four CBD stocks you’ll want to know about.

Few if any industries have been as unstoppable of late as legal marijuana. Since the beginning of 2016, most pot stocks have seen their valuations rise by a triple-digit or quadruple-digit percentage, with global growth estimates for the industry soaring following the legalization of adult-use weed in Canada and multiple medical cannabis legalizations in countries around the globe.

How big could the marijuana industry become? That’s really a matter of interpretation, with a variety of Wall Street investment firms projecting anywhere from $50 billion to $75 billion in sales by the end of the next decade, and the duo of Arcview Market Research and BDS Analytics calling for a compound annual growth rate of nearly 27% between 2019 and 2022.

Image source: Getty Images.

CBD offers a compound annual growth rate of 147% through 2022

However, there’s an even hotter industry that’s budding from within the marijuana movement: cannabidiol (CBD). CBD is the nonpsychoactive cannabinoid best known for its perceived medical benefits, and since it won’t get a user high, it’s become an intriguing means of luring in new consumers who’ve never tried a cannabis-related product before.

According to a report from the Brightfield Group, worldwide CBD sales are expected to soar from $591 million in 2018 to as high as $22 billion by 2022, which works out to a compound annual growth rate of 147%, for those of you keeping score at home.

CBD itself can be extracted from two sources: the cannabis plant and the hemp plant. Generally speaking, hemp is a CBD-rich plant with minimal tetrahydrocannabinol (THC) content. THC is the cannabinoid that gets a user high. Meanwhile, CBD content in cannabis plants can be hit or miss, depending on the strain. CBD derived from hemp plants is legal in all 50 states following the December passage of the Farm Bill, whereas CBD derived from the cannabis plant is still considered illicit at the federal level. However, adding CBD of any form to food, beverages, or dietary supplements is a no-no since it still falls under the guidance of the U.S. Food and Drug Administration (FDA).

Four direct players in the CBD space

With this in mind, here are a handful of stocks that’ll provide investors with direct exposure to the burgeoning CBD market.

Image source: Getty Images.

Charlotte’s Web Holdings

Arguably no company is more attractive from a growth perspective relative to CBD than Charlotte’s Web Holdings (CWBHF -18.65% ) . Charlotte’s Web has the highest retail market share for CBD products in the United States, with access to 3,680 retail stores at the end of 2018.

This is a company that focuses entirely on hemp-extracted CBD, meaning that in one fell swoop, via a signature from Donald Trump on Dec. 20, 2018, all of its products became legal in 50 states, with some kinks to be worked out in the near future regarding CBD as a food and beverage additive. In other words, the Farm Bill’s passage rolled out the green carpet for Charlotte’s Web to get its products into new retail locations. Just about the only thing missing at this point is a brand-name retail partnership.

What isn’t missing are profits. Charlotte’s Web has been profitable on an operating basis for approximately two years, with the company generating $69.5 million in sales in 2018, representing 74% organic sales growth. For 2019 and 2020, Wall Street is looking for a successive more-than-doubling in aggregate sales to $152 million and $313 million, respectively. Again, with Charlotte’s Web already profitable, and CBD products typically yielding much higher margins than traditional dried cannabis flower, this company looks to be in excellent shape.

Image source: Getty Images.

CV Sciences

Another CBD stock that finds itself on the right side of the profit column is CV Sciences (CVSI 4.95% ) .

Like Charlotte’s Web, CV Sciences retails a variety of hemp-derived CBD products in retail stores. According to its full-year results reported about a month ago, the company’s PlusCBD brand of hemp products was available in 2,238 stores at the end of the year, which represents a 45% increase from the end of 2017. However, the passage of the Farm Bill has already opened up new distribution avenues for the company, which means its retail door count should expand significantly in the quarters that lie ahead.

For the year, CV Sciences tallied $48.2 million in sales, up 133% from the prior-year period, while recording net income of $10 million. The lone estimate from Wall Street is forecasting 68% sales growth in 2019 and an additional 47% in 2020, with revenue hitting $119 million by the turn of the decade.

See also  CBD Oil Durham Nc

It is worth noting, though, that CV Sciences is facing possible legal pushback from a drug it’s developing that combines CBD and nicotine as a smokeless tobacco-cessation solution. Short-seller Citron Research, which often has short positions in the stocks it bashes (i.e., a financial interest), released a report in August 2018 showing that CV Sciences’ combo drug patent application had been rejected by the U.S. Patent and Trademark Office. Citron alleges this was never disclosed to investors, which has been grounds for lawsuits. It’s something to keep in mind if you’re considering CV Sciences as a possible investment.

Image source: Getty Images.

Medical Marijuana, Inc.

Even though it’s a tiny tot, another means of gaining direct CBD exposure is by considering penny stock Medical Marijuana, Inc. (MJNA 0.00% ) . Of course, don’t let the company’s $0.066 share price trick you — it has so many shares outstanding that it’s pretty much a bona-fide small-cap with a $238 million market cap.

As the name implies, Medical Marijuana, Inc. supplies hemp-derived products to the U.S., Mexico, and other international markets. This week, Medical Marijuana announced that it had secured about 100 new retail locations during the first quarter, outpacing internal expectations. Like Charlotte’s Web and CV Sciences, the passage of the Farm Bill looks to have played a big role, with CBD acceptance growing and nontraditional retailers willing to carry select CBD products.

Like its peers, Medical Marijuana has seen its top line moving in the right direction. Third-quarter revenue, reported back in November, was slightly over $16.8 million, representing a 116% year-over-year increase. Unfortunately, it hasn’t been profitable on a recurring basis, but it appears to be working toward that mark. In the third quarter, the company generated an operating profit, after expenses, of $0.6 million.

Keep in mind, though, that revaluations of the company’s investment portfolio can wreak havoc on Medical Marijuana, Inc.’s bottom line, and it has resulted in aggregate losses of $158 million through the first nine months of 2018.

Image source: Getty Images.

GW Pharmaceuticals

Lastly, investors can gain direct CBD exposure with the only marijuana stock to have gained FDA approval for a cannabis-derived drug: GW Pharmaceuticals (GWPH) .

In June, the FDA approved GW Pharmaceuticals’ lead CBD-based oral drug known as Epidiolex as a treatment for two rare forms of childhood-onset epilepsy. In multiple late-stage trials, Epidiolex wound up reducing seizure frequency from baseline by between 30% and 40%, which handily topped the effectiveness of the placebo over the defined treatment range. Epidiolex is currently the only drug approved by the FDA to treat Dravet syndrome, and its only potential competitor, Zogenix, had its new drug application for fintepla refused for the time being, giving GW Pharmaceuticals a clear runway to grow sales.

How big could Epidiolex become? That’s up for interpretation, but most Wall Street companies foresee $500 million to perhaps even north of $1 billion in peak annual sales. In the company’s most recent quarter, we learned that GW Pharmaceuticals sold $4.7 million worth of Epidiolex in its first two months on pharmacy shelves. While it’s had little trouble securing insurer coverage for its seizure therapy that costs roughly $32,500 a year, GW Pharmaceuticals is also going to need more than $4.7 million in quarterly sales to maintain a $5-plus billion valuation moving forward.

Sean Williams has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Top Three CBD Stocks to Watch Closely in 2022

There’s a lot of overlap between CBD stocks and pot stocks. Which, of course, makes perfect sense. The cannabis plant has scores of active chemical compounds in it. One of them is delta-9-tetrahydrocannabinol (THC). This is the compound that gets stoners… stoned.

The other big one is cannabidiol (CBD). This compound has no psychoactive properties. But there are a whole lot of potential health benefits. Now, marijuana producers have no need to weed out the CBD. However, companies focusing on CBD do have to keep out the THC if they want to sell their products over the counter. But it’s not terribly difficult if the CBD is derived from industrial hemp. Which, unlike marijuana, is not a controlled substance.

To complicate matters even further, the Food & Drug Administration (FDA) hasn’t compiled a lot of information on CBD. So, it lingers in a state of near-limbo… due, if nothing else, to its close proximity to THC. It’s not quite legal. But based on how easy it is to find CBD products at the local pharmacy, grocery store and coffee shop; it’s obviously not illegal either. However, its legal status can depend on which state you live in.

Here’s how that works…

In 2018, President Trump signed the Agriculture Improvement Act. This is better known as the 2018 Farm Bill. In that act, there was a section that removed hemp from the Controlled Substances Act. Thanks to that bill, CBD – which can be extracted from hemp – was deemed legal on the federal level. The bill targeted the agricultural aspect, though. Compounds extracted from hemp – à la CBD – aren’t privy to the same complete green light as hemp itself. So CBD operates in a mixed jurisdictional realm.

See also  Is CBD Oil Good For Raynaud's

Warning: More Politics & Science Ahead

The federal government won’t arrest folks for growing hemp anymore. Extracting CBD or possessing it isn’t a federal crime anymore either. Well, if there’s less than 0.3% THC content. But not all states see eye to eye with the feds. Some states still want to see more evidence of the benefits and lack of drawbacks. And in some states, CBD remains blacklisted.

But here’s a big feather in the cap of CBD. The Food & Drug Administration has approved a CBD product to treat Lennox-Gastaut syndrome. It’s also been approved to treat Dravet syndrome. To paraphrase, it’s been proven to help those suffering from certain types of epilepsy.

When Greenwich Biosciences received approval for its epilepsy drug, Epidiolex, it was initially considered a controlled substance. Simply because it was derived from marijuana. But when the company requested it be removed from the controlled substances list, the Drug Enforcement Agency (DEA) agreed. This was a big deal because it was the first time the DEA removed any type of cannabis compound from Schedule 1. And this could eventually prove to be a tipping point.

Regardless of what the FDA says, studies have shown that CBD can help to treat insomnia and anxiety. And it can even act as an antidepressant. It has also helped those dealing with chemotherapy and can treat acne. Nonetheless, not everyone remains sold on the prospect of CBD. And at least part of the problem is bad actors.

The FDA had to warn folks to stop claiming CBD could cure the coronavirus. Also, it probably can’t fix “dryness and frizz” in hair or prevent it from turning gray. That’s the kind of claim the FDA is looking out for. And more importantly, we know at this point that it can do some positive things. And here are three companies proving it…

Three CBD Stocks Worth Investing In

  • GW Pharmaceuticals (Nasdaq: GWPH)
  • Charlotte’s Web Holdings (OTC: CWBHF)
  • CV Sciences (OTC: CVSI)

GW Pharmaceuticals

We’ll start with the big one. GW has essentially built its future and reputation on prescription CBD products. It’s the parent company of Greenwich Biosciences – the maker of Epidiolex. It has also received approval of its Sativex therapy in several countries. It’s a multiple sclerosis treatment that is a cannabis-extracted spray containing CBD. It’s used to treat multiple sclerosis.

Even right now, as some of its therapies remain in limbo, GW stock is pricey. But it’s proven to be insulted from the price swings of the marijuana market. The company also has an impressive pipeline of therapies in the works. And approval of them could send this CBD stock skyrocketing.

Charlotte’s Web Holdings

Charlotte’s Web Holdings can be viewed as the indicator of the CBD industry. If CBD sales are on the rise, this CBD stock will be one of the first to indicate it.

The company recently acquired the topical treatment manufacturer Abacus Health Products with the intention of expanding its product line. The plans have already paid off, with net revenue up 1% in 2021. And increasing product lines should only further help the company’s bottom line. This Colorado-based company has deals with major retailers, including Kroger (NYSE: KR), The Vitamin Shoppe and CVS (NYSE: CVS). Once the FDA clears up the regulatory uncertainty surrounding CBD food products, you can expect this stock to soar.

CV Sciences

This company has two distinct segments: consumer products and drug development. The consumer products one is straightforward. It focuses on manufacturing, marketing and selling CBD products. On the other hand, the pharmaceutical division is constantly trying to push the needle and develop novel CBD-based therapeutics. But the company already has the top-selling hemp-derived CBD oil on the market.

CV Sciences’ PlusCBD Oil was the first supplement to receive “generally recognized as safe” (GRAS) status. And the company continues to grow its product line. The company is currently developing synthetic CBD-based medicine and is pursuing FDA approval for drugs. But again, once regulations around CBD are relaxed, this CBD stock is expected to see a major bounce.

The Bottom Line on CBD Stocks

Bills have been introduced to amend the Federal Food, Drug and Cosmetic Act and its regulations of hemp-derived CBD. The best guess as to why they haven’t moved forward is that Congress got distracted by the pandemic. But they should be picked up again. If the FDA finally gets out of the way, these CBD stocks are going to be major beneficiaries.

Unfortunately, for now the prospects of this budding industry are still tied up in politics. And the FDA’s approval (or lack thereof) can change the trajectory of these stocks quickly.

About Matthew Makowski

Matthew Makowski is a senior research analyst and writer at Investment U. He has been studying and writing about the markets for 20 years. Equally comfortable identifying value stocks as he is discounts in the crypto markets, Matthew began mining Bitcoin in 2011 and has since honed his focus on the cryptocurrency markets as a whole. He is a graduate of Rutgers University and lives in Colorado with his dogs Dorito and Pretzel.

See also  Seven CBD Oil

Best CBD Oil Stocks

Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world’s largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company’s Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%). They are considered a leader in the cannabis and tobacco industry.

Jazz Pharmaceuticals ( XNAS: JAZZ )

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and indications in neuroscience and hematology-oncology. Jazz’s product portfolio includes its lead drug, Xyrem, for narcolepsy, Sunosi for improving wakefulness in patients with excessive daytime sleepiness, Defitelio for severe veno-occlusive disease after stem cell transplant, Vyxeos for acute myeloid leukemia, and Zepzelca for small cell lung cancer.

Village Farms Intl ( XNAS: VFF )

As one of the largest and longest-operating greenhouse growers in North America, Village Farms International produces and distributes premium cannabis to national growers in the U.S. and Canada.

The cannabis stock has a market cap of $288 million and trades over 1 million shares per day. It has an EPS of $0.04 and a P/E ratio of 128. Village Farms International generated total revenue of $144 million in 2019, making it one of the best stocks under $10.

Village Farm International recently reported its revenue in Q1 2020 and declared that it has had a profitable business for the 5th consecutive quarter. The cannabis company has also announced that it has expanded its credit facility with its existing lender by $59 million.

GrowGeneration ( XNAS: GRWG )

GrowGeneration Corp. is a premier supplier of cannabis and cannabis-growing equipment. These products include organic nutrients, drip systems, water pumps, air pumps, LED lights and commercial light systems. It is the largest hydroponic supplier in the U.S., with 31 retail and distribution centers.

The cannabis stock has a market cap of $849 million and has an EPS of $0.02. It has an annual dividend yield of $0.02 per share. GrowGeneration has high liquidity and trades more than 1.7 million shares per day. It generated revenue of $79 million in 2019.

AbbVie ( XNYS: ABBV )

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The company’s top drug, Humira, represents close to half of the company’s current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women’s health.

After the legalization of marijuana in the U.S., many companies are actively engaged in the research, development and distribution of cannabis. Cannabidiol (CBD) is the non-psychoactive substance present within cannabis and its products such as CBD oil has had a major impact on the health and wellness industry.

Take a look at these CBD oil stocks that are generating millions of dollars in revenue this year.

Overview: CBD Oil Stocks

Since ancient times, cannabis has been used as a form of medicine and as a means to induce euphoria. Indian sages have also mentioned the medicinal use of marijuana in Vedic hymns of antiquity.

However, President Richard Nixon banned the cultivation and sale of marijuana in the U.S. as part of his “war on drugs” campaign in 1970. It wasn’t until the Compassionate Use Act of 1996 was passed that California became the first state to legalize marijuana to treat people with severe or chronic diseases. As of 2022, 37 states in the U.S. have legalized the medical use of marijuana and 18 states have legalized the recreational use of marijuana.

According to a recent report by the New Frontier Data, the legal sale of cannabis could reach $30 billion by 2025. Due to such high potential to earn profits, alcohol companies have started to invest big in CBD oil companies.

Constellation Brands Inc. (NYSE: STZ) has invested billions in Canopy Growth Corp. (NYSE: CGC). Molson Coors (NYSE: TAP) invested billions in Hexo (TSX: HEXO). Budweiser (NYSE: BUD) entered a joint venture to develop non-alcoholic CBD drinks with Tilray Inc. (NASDAQ: TLRY).

You can still catch up with the market trend and gain some good earnings by investing in CBD oil stocks today.

Best Online Brokers for CBD Oil Stock

Online brokers let you browse and trade thousands of stocks listed on major stock exchanges. These platforms are bundled with tons of educational resources and tools to let you manage your stock portfolio on the go. Many of these online brokers also allow you to trade stocks commission-free.